• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    CVS HEALTH CORPORATION REPORTS THIRD QUARTER 2024 RESULTS

    11/6/24 6:30:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Get the next $CVS alert in real time by email

    Financial Highlights

    • Third quarter total revenues increased to $95.4 billion, up 6.3% compared to the prior year
    • Third quarter GAAP diluted EPS of $0.07 and Adjusted EPS of $1.09
    • Third quarter GAAP diluted EPS and Adjusted EPS include charges to record premium deficiency reserves of approximately $1.1 billion ($0.63 per share) in the Health Care Benefits segment
    • Generated year-to-date cash flow from operations of $7.2 billion

    CEO Commentary

    "Our integrated model accelerates our ability to uniquely do what is most important to today's health care consumers: deliver lower cost of care, a simpler experience and better outcomes. Our third quarter results reflect strong performance in the Health Services and Pharmacy & Consumer Wellness segments, and also highlight the continued need to work across our enterprise and address macro challenges to the Health Care Benefits segment. My commitment to our CVS Health colleagues and our customers is to drive focused execution of our integrated strategy to improve the health of the 185 million people we are privileged to serve."

    — David Joyner, CVS Health President and CEO

    WOONSOCKET, R.I., Nov. 6, 2024 /PRNewswire/ -- CVS Health Corporation (NYSE:CVS) today announced operating results for the three months ended September 30, 2024.

    Financial Results Summary



    Three Months Ended

    September 30,

    In millions, except per share amounts

    2024



    2023



    Change

    Total revenues 

    $         95,428



    $         89,764



    $           5,664

    Operating income

    832



    3,690



    (2,858)

    Adjusted operating income (1)

    2,547



    4,456



    (1,909)

    Diluted earnings per share

    $             0.07



    $             1.75



    $           (1.68)

    Adjusted EPS (2)

    $             1.09



    $             2.21



    $           (1.12)

    Third quarter GAAP diluted EPS of $0.07 decreased from $1.75 in the prior year and Adjusted EPS of $1.09 decreased from $2.21 in the prior year, primarily due to a decline in the Health Care Benefits segment's operating results, which reflect continued utilization pressure and premium deficiency reserves of approximately $1.1 billion recorded in the third quarter of 2024, related to anticipated losses in the fourth quarter of 2024 within the Medicare and individual exchange product lines. The premium deficiency reserves are expected to be substantially released during the fourth quarter of 2024, benefiting results in that period.

    The Company presents both GAAP and non-GAAP financial measures in this press release to assist in the comparison of the Company's past financial performance with its current financial performance. See "Non-GAAP Financial Information" beginning on page 11 and endnotes beginning on page 22 for explanations of non-GAAP financial measures presented in this press release. See pages 13 through 15 for reconciliations of each non-GAAP financial measure used in this release to the most directly comparable GAAP financial measure.

    Consolidated third quarter results



    Three Months Ended

    September 30,



    Nine Months Ended

    September 30,

    In millions, except per share amounts

    2024



    2023



    Change



    2024



    2023



    Change

    Total revenues 

    $  95,428



    $  89,764



    $    5,664



    $ 275,099



    $ 263,963



    $  11,136

    Operating income

    832



    3,690



    (2,858)



    6,148



    10,370



    (4,222)

    Adjusted operating income (1)

    2,547



    4,456



    (1,909)



    9,248



    13,307



    (4,059)

    Net income

    71



    2,265



    (2,194)



    2,963



    6,321



    (3,358)

    Diluted earnings per share

    $      0.07



    $      1.75



    $     (1.68)



    $      2.35



    $      4.88



    $     (2.53)

    Adjusted EPS (2)

    $      1.09



    $      2.21



    $     (1.12)



    $      4.23



    $      6.62



    $     (2.39)

    For the three months ended September 30, 2024 compared to the prior year:

    • Total revenues increased 6.3% primarily driven by growth in the Health Care Benefits and Pharmacy & Consumer Wellness segments, partially offset by a decline in the Health Services segment.
    • Operating income decreased 77.5% primarily due to the decrease in adjusted operating income described below and restructuring charges of approximately $1.2 billion recorded in the current year.
    • Adjusted operating income decreased 42.8% driven by a decline in the Health Care Benefits segment, primarily due to increased utilization and premium deficiency reserves recorded in the third quarter of 2024 related to anticipated losses in the fourth quarter of 2024, partially offset by increases in the Health Services and Pharmacy & Consumer Wellness segments. See pages 3 through 5 for additional discussion of the adjusted operating income performance of the Company's segments.
    • Interest expense increased $59 million, or 8.5%, due to higher debt in the three months ended September 30, 2024, primarily driven by long-term debt issued in May 2024.
    • The effective income tax rate increased to 32.4% compared to 25.0% primarily due to lower pre-tax income in the three months ended September 30, 2024 compared to the prior year.

    Restructuring program

    • During the third quarter of 2024, the Company finalized an enterprise-wide restructuring plan intended to streamline and simplify the organization, improve efficiency and reduce costs. In connection with this restructuring plan, during the three months ended September 30, 2024, the Company recorded restructuring charges of approximately $1.2 billion, comprised of a $607 million store impairment charge for additional retail pharmacy stores it plans to close in 2025, $293 million of costs associated with corporate workforce optimization, including severance and employee-related costs, and $269 million of other asset impairments and related charges associated with the discontinuation of certain non-core assets.

    Health Care Benefits segment

    The Health Care Benefits segment offers a full range of insured and self-insured ("ASC") medical, pharmacy, dental and behavioral health products and services. The segment results for the three and nine months ended September 30, 2024 and 2023 were as follows:



    Three Months Ended

    September 30,



    Nine Months Ended

    September 30,

    In millions, except percentages

    2024



    2023



    Change



    2024



    2023



    Change

    Total revenues

    $  32,996



    $  26,296



    $    6,700



    $  97,707



    $  78,920



    $  18,787

    Adjusted operating income (loss) (1)

    (924)



    1,536



    (2,460)



    746



    4,901



    (4,155)

    Medical benefit ratio ("MBR") (3)

    95.2 %



    85.7 %



    9.5 %



    91.7 %



    85.5 %



    6.2 %

    Medical membership (4)













    27.1



    25.7



    1.4

    • Total revenues increased 25.5% for the three months ended September 30, 2024 compared to the prior year driven by growth in the Medicare and Commercial product lines.
    • During the third quarter of 2024, the Company recorded premium deficiency reserves of approximately $1.1 billion, primarily in its Medicare and individual exchange product lines related to anticipated losses for the 2024 coverage year. The $1.1 billion premium deficiency recorded was comprised of $394 million of operating expenses related to the write-off of unamortized acquisition costs and $670 million of health care costs.
    • During the three months ended September 30, 2024, the Health Care Benefits segment had an adjusted operating loss of $924 million compared to adjusted operating income of $1.5 billion in the prior year. The change was primarily driven by increased utilization, the approximately $1.1 billion of premium deficiency reserves described above, the impact of higher acuity in Medicaid following the resumption of redeterminations and the unfavorable impact of the previously disclosed decline in the Company's Medicare Advantage star ratings for the 2024 payment year. These decreases were partially offset by an increase in net investment income.
    • The MBR increased to 95.2% in the three months ended September 30, 2024 compared to 85.7% in the prior year driven by increased utilization, the $670 million (220 basis points) of premium deficiency reserves recorded as health care costs described above, higher acuity in Medicaid and the unfavorable impact of the Company's Medicare Advantage star ratings for the 2024 payment year.
    • Medical membership as of September 30, 2024 of 27.1 million increased 178,000 members compared with June 30, 2024, reflecting increases in the Commercial and Medicare product lines.
    • Prior years' health care costs payable estimates developed favorably by $788 million during the nine months ended September 30, 2024. This development is reported on a basis consistent with the prior years' development reported in the health care costs payable table in the Company's annual audited financial statements and does not directly correspond to an increase in 2024 operating results.
    • Days claims payable were 44.6 days as of September 30, 2024, a increase of 1.5 days compared to June 30, 2024. The increase was primarily driven by the impact of the premium deficiency reserves recorded as health care costs in the third quarter of 2024 described above.
    • The U.S. Centers for Medicare & Medicaid Services ("CMS") released the Company's 2025 star ratings in October 2024. The Company's 2025 star ratings will be used to determine which of the Company's Medicare Advantage plans have ratings of four stars or higher and qualify for bonus payments in 2026. Based on the Company's membership as of September 2024, 88% of the Company's Medicare Advantage members were in plans with 2025 star ratings of at least 4.0 stars, compared to 87% of the Company's Medicare Advantage members being in plans with 2024 star ratings of at least 4.0 stars based on the Company's membership as of September 2023.

    See the supplemental information on page 17 for additional information regarding the performance of the Health Care Benefits segment.

    Health Services segment

    The Health Services segment provides a full range of pharmacy benefit management solutions, delivers health care services in its medical clinics, virtually, and in the home, and offers provider enablement solutions. The segment results for the three and nine months ended September 30, 2024 and 2023 were as follows:



    Three Months Ended

    September 30,



    Nine Months Ended

    September 30,

    In millions

    2024



    2023



    Change



    2024



    2023



    Change

    Total revenues

    $  44,129



    $  46,891



    $   (2,762)



    $ 126,585



    $ 137,697



    $ (11,112)

    Adjusted operating income (1)

    2,204



    1,878



    326



    5,482



    5,452



    30

    Pharmacy claims processed (5) (6)

    484.1



    579.6



    (95.5)



    1,418.2



    1,743.5



    (325.3)

    • Total revenues decreased 5.9% for the three months ended September 30, 2024 compared to the prior year primarily driven by the previously announced loss of a large client and continued pharmacy client price improvements. These decreases were partially offset by pharmacy drug mix, increased contributions from the Company's health care delivery assets and growth in specialty pharmacy.
    • Adjusted operating income increased 17.4% for the three months ended September 30, 2024 compared to the prior year primarily driven by improved purchasing economics, partially offset by continued pharmacy client price improvements and the previously announced loss of a large client.
    • Pharmacy claims processed decreased 16.5% on a 30-day equivalent basis for the three months ended September 30, 2024 compared to the prior year, reflecting the previously announced loss of a large client.

    See the supplemental information on page 18 for additional information regarding the performance of the Health Services segment.

    Pharmacy & Consumer Wellness segment

    The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations, provides ancillary pharmacy services including pharmacy patient care programs, diagnostic testing and vaccination administration, and sells a wide assortment of health and wellness products and general merchandise. The segment also provides pharmacy services to long-term care facilities and pharmacy fulfillment services to support the Health Services segment's specialty and mail order pharmacy offerings. The segment results for the three and nine months ended September 30, 2024 and 2023 were as follows:



    Three Months Ended

    September 30,



    Nine Months Ended

    September 30,

    In millions

    2024



    2023



    Change



    2024



    2023



    Change

    Total revenues

    $  32,423



    $  28,872



    $    3,551



    $  90,986



    $  85,578



    $    5,408

    Adjusted operating income (1)

    1,596



    1,389



    207



    4,016



    3,936



    80

    Prescriptions filled (5) (6)

    431.6



    407.1



    24.5



    1,269.6



    1,217.6



    52.0

    • Total revenues increased 12.3% for the three months ended September 30, 2024 compared to the prior year primarily driven by increased prescription volume, including increased contributions from vaccinations, and pharmacy drug mix. These increases were partially offset by continued pharmacy reimbursement pressure, the impact of recent generic introductions and decreased front store volume, including the impact of a decrease in store count.
    • Adjusted operating income increased 14.9% for the three months ended September 30, 2024 compared to the prior year primarily driven by increased prescription volume, including increased contributions from vaccinations, as well as improved drug purchasing. These increases were partially offset by continued pharmacy reimbursement pressure and decreased front store volume in the three months ended September 30, 2024.
    • Prescriptions filled increased 6.0% on a 30-day equivalent basis for the three months ended September 30, 2024 compared to the prior year primarily driven by increased utilization.
    • Same store prescription volume(6)(12) increased 9.1% on a 30-day equivalent basis for the three months ended September 30, 2024 compared to the prior year.

    See the supplemental information on page 19 for additional information regarding the performance of the Pharmacy & Consumer Wellness segment.

    Teleconference and webcast

    The Company will be holding a conference call today for investors at 8:00 a.m. (Eastern Time) to discuss its third quarter results. An audio webcast of the call will be broadcast simultaneously for all interested parties through the Investor Relations section of the CVS Health website at http://investors.cvshealth.com. This webcast will be archived and available on the website for a one-year period following the conference call.

    About CVS Health

    CVS Health is the leading health solutions company, delivering care like no one else can. We reach more people and improve the health of communities across America through our local presence, digital channels and over 300,000 dedicated colleagues – including more than 40,000 physicians, pharmacists, nurses and nurse practitioners. Wherever and whenever people need us, we help them with their health – whether that's managing chronic diseases, staying compliant with their medications or accessing affordable health and wellness services in the most convenient ways. We help people navigate the health care system – and their personal health care – by improving access, lowering costs and being a trusted partner for every meaningful moment of health. And we do it all with heart, each and every day. Follow @CVSHealth on social media.

    Cautionary statement concerning forward-looking statements

    The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by or on behalf of CVS Health Corporation. Statements in this press release that are forward-looking include, but are not limited to, the information under the headings "CEO Commentary" and "Financial Results Summary" and the information included in the reconciliations and endnotes. By their nature, all forward-looking statements are not guarantees of future performance or results and are subject to risks and uncertainties that are difficult to predict and/or quantify. Actual results may differ materially from those contemplated by the forward-looking statements due to the risks and uncertainties described in our Securities and Exchange Commission ("SEC") filings, including those set forth in the Risk Factors section and under the heading "Cautionary Statement Concerning Forward-Looking Statements" in our most recently filed Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2024, June 30, 2024 and September 30, 2024 and our Current Reports on Form 8-K.

    You are cautioned not to place undue reliance on CVS Health's forward-looking statements. CVS Health's forward-looking statements are and will be based upon management's then-current views and assumptions regarding future events and operating performance, and are applicable only as of the dates of such statements. CVS Health does not assume any duty to update or revise forward-looking statements, whether as a result of new information, future events, uncertainties or otherwise.

    - Tables Follow -

    CVS HEALTH CORPORATION

    Condensed Consolidated Statements of Operations

    (Unaudited)





    Three Months Ended

    September 30,



    Nine Months Ended

    September 30,

    In millions, except per share amounts

    2024



    2023



    2024



    2023

    Revenues:















    Products

    $      59,674



    $      61,298



    $    169,610



    $    179,984

    Premiums

    30,925



    24,657



    91,983



    74,117

    Services

    4,279



    3,532



    12,108



    8,977

    Net investment income

    550



    277



    1,398



    885

    Total revenues

    95,428



    89,764



    275,099



    263,963

    Operating costs:















    Cost of products sold

    52,948



    54,688



    151,019



    159,679

    Health care costs

    29,922



    21,499



    85,578



    63,729

    Operating expenses

    10,557



    9,876



    31,185



    29,329

    Restructuring charges

    1,169



    11



    1,169



    507

    Loss on assets held for sale

    —



    —



    —



    349

    Total operating costs

    94,596



    86,074



    268,951



    253,593

    Operating income

    832



    3,690



    6,148



    10,370

    Interest expense

    752



    693



    2,200



    1,968

    Other income

    (25)



    (22)



    (74)



    (66)

    Income before income tax provision

    105



    3,019



    4,022



    8,468

    Income tax provision

    34



    754



    1,059



    2,147

    Net income

    71



    2,265



    2,963



    6,321

    Net (income) loss attributable to noncontrolling interests

    16



    (4)



    7



    (23)

    Net income attributable to CVS Health

    $            87



    $        2,261



    $        2,970



    $        6,298

















    Net income per share attributable to CVS Health:















    Basic

    $         0.07



    $         1.76



    $         2.36



    $         4.90

    Diluted

    $         0.07



    $         1.75



    $         2.35



    $         4.88

    Weighted average shares outstanding:















    Basic

    1,259



    1,287



    1,258



    1,284

    Diluted

    1,259



    1,290



    1,262



    1,289

    Dividends declared per share

    $        0.665



    $        0.605



    $        1.995



    $        1.815

     

    CVS HEALTH CORPORATION

    Condensed Consolidated Balance Sheets

    (Unaudited)



    In millions

    September 30,

    2024



    December 31,

    2023

    Assets:







    Cash and cash equivalents

    $             6,875



    $             8,196

    Investments

    2,805



    3,259

    Accounts receivable, net

    36,179



    35,227

    Inventories

    17,649



    18,025

    Other current assets

    3,835



    3,151

    Total current assets

    67,343



    67,858

    Long-term investments

    28,939



    23,019

    Property and equipment, net

    12,728



    13,183

    Operating lease right-of-use assets

    16,231



    17,252

    Goodwill

    91,272



    91,272

    Intangible assets, net

    27,817



    29,234

    Separate accounts assets

    3,334



    3,250

    Other assets

    4,763



    4,660

    Total assets

    $         252,427



    $         249,728









    Liabilities:







    Accounts payable

    $           15,713



    $           14,897

    Pharmacy claims and discounts payable

    23,917



    22,874

    Health care costs payable

    15,237



    12,049

    Policyholders' funds

    913



    1,326

    Accrued expenses

    20,174



    22,189

    Other insurance liabilities

    1,051



    1,141

    Current portion of operating lease liabilities

    1,912



    1,741

    Short-term debt

    800



    200

    Current portion of long-term debt

    4,910



    2,772

    Total current liabilities

    84,627



    79,189

    Long-term operating lease liabilities

    15,258



    16,034

    Long-term debt

    59,824



    58,638

    Deferred income taxes

    3,632



    4,311

    Separate accounts liabilities

    3,334



    3,250

    Other long-term insurance liabilities

    5,162



    5,459

    Other long-term liabilities

    5,484



    6,211

    Total liabilities

    177,321



    173,092









    Shareholders' equity:







    Preferred stock

    —



    —

    Common stock and capital surplus

    49,510



    48,992

    Treasury stock

    (36,813)



    (33,838)

    Retained earnings

    62,038



    61,604

    Accumulated other comprehensive income (loss)

    209



    (297)

    Total CVS Health shareholders' equity

    74,944



    76,461

    Noncontrolling interests

    162



    175

    Total shareholders' equity

    75,106



    76,636

    Total liabilities and shareholders' equity

    $         252,427



    $         249,728

     

    CVS HEALTH CORPORATION

    Condensed Consolidated Statements of Cash Flows

    (Unaudited)





    Nine Months Ended

    September 30,

    In millions

    2024



    2023

    Cash flows from operating activities:







    Cash receipts from customers

    $      264,538



    $      260,300

    Cash paid for inventory, prescriptions dispensed and health services rendered

    (145,469)



    (153,051)

    Insurance benefits paid

    (80,357)



    (61,658)

    Cash paid to other suppliers and employees

    (28,933)



    (26,038)

    Interest and investment income received

    1,288



    1,174

    Interest paid

    (2,391)



    (2,049)

    Income taxes paid

    (1,429)



    (2,616)

    Net cash provided by operating activities

    7,247



    16,062









    Cash flows from investing activities:







    Proceeds from sales and maturities of investments

    7,634



    5,547

    Purchases of investments

    (12,677)



    (6,625)

    Purchases of property and equipment

    (2,013)



    (2,120)

    Acquisitions (net of cash and restricted cash acquired)

    (85)



    (16,492)

    Other

    75



    43

    Net cash used in investing activities

    (7,066)



    (19,647)









    Cash flows from financing activities:







    Commercial paper borrowings (repayments), net

    600



    —

    Proceeds from issuance of short-term loan

    —



    5,000

    Repayment of short-term loan

    —



    (5,000)

    Proceeds from issuance of long-term debt

    4,959



    10,898

    Repayments of long-term debt

    (1,706)



    (2,734)

    Repurchase of common stock

    (3,023)



    (2,013)

    Dividends paid

    (2,535)



    (2,353)

    Proceeds from exercise of stock options

    342



    242

    Payments for taxes related to net share settlement of equity awards

    (181)



    (175)

    Other

    (22)



    (210)

    Net cash provided by (used in) financing activities

    (1,566)



    3,655

    Net increase (decrease) in cash, cash equivalents and restricted cash

    (1,385)



    70

    Cash, cash equivalents and restricted cash at the beginning of the period

    8,525



    13,305

    Cash, cash equivalents and restricted cash at the end of the period

    $         7,140



    $       13,375

     

    CVS HEALTH CORPORATION

    Condensed Consolidated Statements of Cash Flows

    (Unaudited)





    Nine Months Ended

    September 30,

    In millions

    2024



    2023

    Reconciliation of net income to net cash provided by operating activities:







    Net income

    $         2,963



    $         6,321

    Adjustments required to reconcile net income to net cash provided by operating activities:







    Depreciation and amortization

    3,450



    3,232

    Stock-based compensation

    403



    461

    Restructuring charges (impairment of long-lived assets)

    840



    152

    Deferred income taxes and other items

    (912)



    (163)

    Change in operating assets and liabilities, net of effects from acquisitions:







    Accounts receivable, net

    (986)



    (3,920)

    Inventories

    355



    1,305

    Other assets

    (850)



    (518)

    Accounts payable and pharmacy claims and discounts payable

    2,169



    2,466

    Health care costs payable and other insurance liabilities

    2,878



    4,679

    Other liabilities

    (3,063)



    2,047

    Net cash provided by operating activities

    $         7,247



    $       16,062

    Non-GAAP Financial Information

    The Company uses non-GAAP financial measures to analyze underlying business performance and trends. The Company believes that providing these non-GAAP financial measures enhances the Company's and investors' ability to compare the Company's past financial performance with its current and expected future performance. These non-GAAP financial measures, which are included in this press release and which may be referred to on the conference call discussing the Company's third quarter financial results, are provided as supplemental information to the financial measures presented in this press release and discussed on the conference call that are calculated and presented in accordance with GAAP. Non-GAAP financial measures should not be considered a substitute for, or superior to, financial measures determined or calculated in accordance with GAAP. The Company's definitions of its non-GAAP financial measures may not be comparable to similarly titled measures reported by other companies.

    Non-GAAP financial measures such as consolidated adjusted operating income, adjusted earnings per share ("EPS") and adjusted income attributable to CVS Health exclude from the relevant GAAP metrics, as applicable: amortization of intangible assets, net realized capital gains or losses and other items, if any, that neither relate to the ordinary course of the Company's business nor reflect the Company's underlying business performance.

    For the periods covered in this press release, the following items are excluded from the non-GAAP financial measures described above, as applicable, because the Company believes they neither relate to the ordinary course of the Company's business nor reflect the Company's underlying business performance:

    • The Company's acquisition activities have resulted in the recognition of intangible assets as required under the acquisition method of accounting which consist primarily of trademarks, customer contracts/relationships, covenants not to compete, technology, provider networks and value of business acquired. Definite-lived intangible assets are amortized over their estimated useful lives and are tested for impairment when events indicate that the carrying value may not be recoverable. The amortization of intangible assets is reflected in the unaudited condensed consolidated statements of operations in operating expenses within each segment. Although intangible assets contribute to the Company's revenue generation, the amortization of intangible assets does not directly relate to the underwriting of the Company's insurance products, the services performed for the Company's customers or the sale of the Company's products or services. Additionally, intangible asset amortization expense typically fluctuates based on the size and timing of the Company's acquisition activity. Accordingly, the Company believes excluding the amortization of intangible assets enhances the Company's and investors' ability to compare the Company's past financial performance with its current performance and to analyze underlying business performance and trends. Intangible asset amortization excluded from the related non-GAAP financial measure represents the entire amount recorded within the Company's GAAP financial statements, and the revenue generated by the associated intangible assets has not been excluded from the related non-GAAP financial measure. Intangible asset amortization is excluded from the related non-GAAP financial measure because the amortization, unlike the related revenue, is not affected by operations of any particular period unless an intangible asset becomes impaired or the estimated useful life of an intangible asset is revised.
    • The Company's net realized capital gains and losses arise from various types of transactions, primarily in the course of managing a portfolio of assets that support the payment of insurance liabilities. Net realized capital gains and losses are reflected in the unaudited condensed consolidated statements of operations in net investment income (loss) within each segment. These capital gains and losses are the result of investment decisions, market conditions and other economic developments that are unrelated to the performance of the Company's business, and the amount and timing of these capital gains and losses do not directly relate to the underwriting of the Company's insurance products, the services performed for the Company's customers or the sale of the Company's products or services. Accordingly, the Company believes excluding net realized capital gains and losses enhances the Company's and investors' ability to compare the Company's past financial performance with its current performance and to analyze underlying business performance and trends.
    • During the three and nine months ended September 30, 2024, the acquisition-related integration costs relate to the acquisitions of Signify Health and Oak Street Health. During the three and nine months ended September 30, 2023, the acquisition-related transaction and integration costs relate to the acquisitions of Signify Health and Oak Street Health. The acquisition-related transaction and integration costs are reflected in the Company's unaudited condensed consolidated statements of operations in operating expenses within the Corporate/Other segment.
    • During the three and nine months ended September 30, 2024, the restructuring charges are primarily comprised of a store impairment charge, corporate workforce optimization costs, including severance and employee-related costs, and other asset impairment and related charges associated with the discontinuation of certain non-core assets. During the third quarter of 2024, the Company finalized an enterprise-wide restructuring plan intended to streamline and simplify the organization, improve efficiency and reduce costs. In connection with this restructuring plan, the Company completed a strategic review of its retail business and determined that it plans to close additional retail stores in 2025, and, accordingly, it recorded a store impairment charge to write down the associated operating lease right-of-use assets and property and equipment. In addition, during the third quarter of 2024, the Company also conducted a review of its various strategic assets and determined that it would discontinue the use of certain non-core assets, at which time impairment losses were recorded to write down the carrying value of these assets to the Company's best estimate of their fair value. During the three months ended September 30, 2023, the restructuring charges are primarily comprised of a stock-based compensation charge. During the nine months ended September 30, 2023, the restructuring charges also include severance and employee-related costs and asset impairment charges. The restructuring charges associated with the store impairments are reflected within the Pharmacy & Consumer Wellness segment, other asset impairments and related charges are reflected within the Corporate/Other and Pharmacy & Consumer Wellness segments and corporate workforce optimization costs are reflected within the Corporate/Other segment.
    • During the three and nine months ended September 30, 2024 and 2023, the office real estate optimization charges primarily relate to the abandonment of leased real estate and the related right-of-use assets and property and equipment in connection with the Company's continuous evaluation of corporate office real estate space in response to its ongoing flexible work arrangement. The office real estate optimization charges are reflected in the Company's unaudited condensed consolidated statements of operations in operating expenses within each segment.
    • During the nine months ended September 30, 2024, the opioid litigation charge relates to a change in the Company's accrual related to ongoing opioid litigation matters.
    • During the nine months ended September 30, 2023, the loss on assets held for sale relates to the long-term care ("LTC") reporting unit within the Pharmacy & Consumer Wellness segment. During 2022, the Company determined that its LTC business was no longer a strategic asset and committed to a plan to sell it, at which time the LTC business met the criteria for held-for-sale accounting and its net assets were accounted for as assets held for sale. During the first quarter of 2023, a loss on assets held for sale was recorded to write down the carrying value of the LTC business to the Company's best estimate of the ultimate selling price which reflected its estimated fair value less costs to sell. As of the third quarter of 2023, the Company determined the LTC business no longer met the criteria for held-for-sale accounting and accordingly the net assets associated with the LTC business were reclassified to held and used at their respective fair values.
    • The corresponding tax benefit or expense related to the items excluded from adjusted income attributable to CVS Health and Adjusted EPS above. The nature of each non-GAAP adjustment is evaluated to determine whether a discrete adjustment should be made to the adjusted income tax provision.

    See endnotes (1) and (2) on page 22 for definitions of non-GAAP financial measures. Reconciliations of each non-GAAP financial measure to the most directly comparable GAAP financial measure are presented on pages 13 through 15.

     

    Reconciliations of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial Measures



    Adjusted Operating Income

    (Unaudited)



    The following are reconciliations of consolidated operating income (GAAP measure) to consolidated adjusted operating income, as well as reconciliations of segment GAAP operating income (loss) to segment adjusted operating income (loss):





    Three Months Ended September 30, 2024

    In millions

    Health Care

    Benefits



    Health

    Services



    Pharmacy &

    Consumer

    Wellness



    Corporate/

    Other



    Consolidated

    Totals

    Operating income (loss) (GAAP measure)

    $        (1,229)



    $       2,055



    $                784



    $          (778)



    $                832

    Amortization of intangible assets

    294



    149



    64



    —



    507

    Net realized capital (gains) losses

    1



    —



    —



    (20)



    (19)

    Acquisition-related integration costs

    —



    —



    —



    41



    41

    Restructuring charges

    —



    —



    747



    422



    1,169

    Office real estate optimization charges

    10



    —



    1



    6



    17

    Adjusted operating income (loss) (1)

    $            (924)



    $       2,204



    $            1,596



    $          (329)



    $            2,547







    Three Months Ended September 30, 2023

    In millions

    Health Care

    Benefits



    Health

    Services



    Pharmacy &

    Consumer

    Wellness



    Corporate/

    Other



    Consolidated

    Totals

    Operating income (loss) (GAAP measure)

    $          1,115



    $       1,727



    $            1,322



    $          (474)



    $            3,690

    Amortization of intangible assets

    294



    150



    65



    —



    509

    Net realized capital losses

    119



    —



    2



    21



    142

    Acquisition-related transaction and

    integration costs

    —



    —



    —



    94



    94

    Restructuring charges

    —



    —



    —



    11



    11

    Office real estate optimization charges

    8



    1



    —



    1



    10

    Adjusted operating income (loss) (1)

    $          1,536



    $       1,878



    $            1,389



    $          (347)



    $            4,456







    Nine Months Ended September 30, 2024

    In millions

    Health Care

    Benefits



    Health

    Services



    Pharmacy &

    Consumer

    Wellness



    Corporate/

    Other



    Consolidated

    Totals

    Operating income (loss) (GAAP measure)

    $            (227)



    $       5,034



    $            3,076



    $      (1,735)



    $            6,148

    Amortization of intangible assets

    881



    448



    192



    1



    1,522

    Net realized capital losses

    82



    —



    —



    7



    89

    Acquisition-related integration costs

    —



    —



    —



    203



    203

    Restructuring charges

    —



    —



    747



    422



    1,169

    Office real estate optimization charges

    10



    —



    1



    6



    17

    Opioid litigation charge

    —



    —



    —



    100



    100

    Adjusted operating income (loss) (1)

    $              746



    $       5,482



    $            4,016



    $          (996)



    $            9,248







    Nine Months Ended September 30, 2023

    In millions

    Health Care

    Benefits



    Health

    Services



    Pharmacy &

    Consumer

    Wellness



    Corporate/

    Other



    Consolidated

    Totals

    Operating income (loss) (GAAP measure)

    $          3,683



    $       5,132



    $            3,388



    $      (1,833)



    $          10,370

    Amortization of intangible assets

    883



    316



    195



    2



    1,396

    Net realized capital losses

    296



    —



    4



    45



    345

    Acquisition-related transaction and integration costs

    —



    —



    —



    294



    294

    Restructuring charges

    —



    —



    —



    507



    507

    Office real estate optimization charges

    39



    4



    —



    3



    46

    Loss on assets held for sale

    —



    —



    349



    —



    349

    Adjusted operating income (loss) (1)

    $          4,901



    $       5,452



    $            3,936



    $          (982)



    $          13,307

     

    Adjusted Earnings Per Share

    (Unaudited)



    The following are reconciliations of net income attributable to CVS Health to adjusted income attributable to CVS Health and calculations of GAAP diluted EPS and Adjusted EPS: 





    Three Months Ended

    September 30, 2024



    Three Months Ended

    September 30, 2023

    In millions, except per share amounts

    Total

    Company



    Per

    Common

    Share



    Total

    Company



    Per

    Common

    Share

    Net income attributable to CVS Health (GAAP measure)

    $          87



    $        0.07



    $      2,261



    $        1.75

    Amortization of intangible assets

    507



    0.40



    509



    0.39

    Net realized capital (gains) losses

    (19)



    (0.02)



    142



    0.11

    Acquisition-related transaction and integration costs

    41



    0.03



    94



    0.07

    Restructuring charges

    1,169



    0.93



    11



    0.01

    Office real estate optimization charges

    17



    0.01



    10



    0.01

    Tax impact of non-GAAP adjustments

    (433)



    (0.33)



    (177)



    (0.13)

    Adjusted income attributable to CVS Health (2)

    $      1,369



    $        1.09



    $      2,850



    $        2.21

















    Weighted average diluted shares outstanding





    1,259







    1,290



















    Nine Months Ended

    September 30, 2024



    Nine Months Ended

    September 30, 2023

    In millions, except per share amounts

    Total

    Company



    Per

    Common

    Share



    Total

    Company



    Per

    Common

    Share

    Net income attributable to CVS Health (GAAP measure)

    $      2,970



    $        2.35



    $      6,298



    $        4.88

    Amortization of intangible assets

    1,522



    1.21



    1,396



    1.08

    Net realized capital losses

    89



    0.07



    345



    0.27

    Acquisition-related transaction and integration costs

    203



    0.16



    294



    0.23

    Restructuring charges

    1,169



    0.93



    507



    0.39

    Office real estate optimization charges

    17



    0.01



    46



    0.04

    Opioid litigation charge

    100



    0.08



    —



    —

    Loss on assets held for sale

    —



    —



    349



    0.27

    Tax impact of non-GAAP adjustments

    (738)



    (0.58)



    (701)



    (0.54)

    Adjusted income attributable to CVS Health (2)

    $      5,332



    $        4.23



    $      8,534



    $        6.62

















    Weighted average diluted shares outstanding





    1,262







    1,289

     

    Supplemental Information

    (Unaudited)

    The Company's segments maintain separate financial information, and the Company's chief operating decision maker (the "CODM") evaluates the segments' operating results on a regular basis in deciding how to allocate resources among the segments and in assessing segment performance. The CODM evaluates the performance of the Company's segments based on adjusted operating income. Adjusted operating income is defined as operating income (GAAP measure) excluding the impact of amortization of intangible assets, net realized capital gains or losses and other items, if any, that neither relate to the ordinary course of the Company's business nor reflect the Company's underlying business performance as further described in endnote (1). The CODM uses adjusted operating income as its principal measure of segment performance as it enhances the CODM's ability to compare past financial performance with current performance and analyze underlying business performance and trends.

    The following are reconciliations of financial measures of the Company's segments to the consolidated totals:

    In millions

    Health Care

    Benefits



    Health

    Services (a)



    Pharmacy &

    Consumer

    Wellness



    Corporate/

    Other



    Intersegment

    Eliminations (b)



    Consolidated

    Totals

    Three Months Ended























    September 30, 2024























    Total revenues

    $     32,996



    $   44,129



    $         32,423



    $        142



    $        (14,262)



    $      95,428

    Adjusted operating income (loss) (1)

    (924)



    2,204



    1,596



    (329)



    —



    2,547

    September 30, 2023























    Total revenues

    $     26,296



    $   46,891



    $         28,872



    $        105



    $        (12,400)



    $      89,764

    Adjusted operating

    income (loss) (1)

    1,536



    1,878



    1,389



    (347)



    —



    4,456

























    Nine Months Ended























    September 30, 2024























    Total revenues

    $     97,707



    $ 126,585



    $         90,986



    $        368



    $        (40,547)



    $     275,099

    Adjusted operating income (loss) (1)

    746



    5,482



    4,016



    (996)



    —



    9,248

    September 30, 2023























    Total revenues

    $     78,920



    $ 137,697



    $         85,578



    $        376



    $        (38,608)



    $     263,963

    Adjusted operating income (loss) (1)

    4,901



    5,452



    3,936



    (982)



    —



    13,307

    _____________________________________________

    (a)

    Total revenues of the Health Services segment include approximately $2.7 billion and $3.2 billion of retail co-payments for the three months ended September 30, 2024 and 2023, respectively, and $8.9 billion and $10.7 billion of retail co-payments for the nine months ended September 30, 2024 and 2023, respectively.

    (b)

    Intersegment revenue eliminations relate to intersegment revenue generating activities that occur between the Health Care Benefits segment, the Health Services segment, and/or the Pharmacy & Consumer Wellness segment.

     

    Supplemental Information

    (Unaudited)



    Health Care Benefits segment



    The following table summarizes the Health Care Benefits segment's performance for the respective periods:













    Change



    Three Months Ended

    September 30,



    Nine Months Ended

    September 30,



    Three Months Ended

    September 30,

    2024 vs 2023



    Nine Months Ended

    September 30,

    2024 vs 2023

    In millions, except percentages and basis points ("bps")

    2024



    2023



    2024



    2023



    $



    %



    $



    %

    Revenues:































    Premiums

    $ 30,914



    $ 24,645



    $  91,947



    $  74,079



    $    6,269



    25.4 %



    $ 17,868



    24.1 %

    Services

    1,659



    1,464



    4,684



    4,285



    195



    13.3 %



    399



    9.3 %

    Net investment income

    423



    187



    1,076



    556



    236



    126.2 %



    520



    93.5 %

    Total revenues

    32,996



    26,296



    97,707



    78,920



    6,700



    25.5 %



    18,787



    23.8 %

    Health care costs

    29,443



    21,114



    84,359



    63,329



    8,329



    39.4 %



    21,030



    33.2 %

    MBR (Health care costs as a % of premium revenues) (3)

    95.2 %



    85.7 %



    91.7 %



    85.5 %



    950

    bps



    620

    bps

    Operating expenses

    $   4,782



    $   4,067



    $  13,575



    $  11,908



    $        715



    17.6 %



    $   1,667



    14.0 %

    Operating expenses as a % of total revenues

    14.5 %



    15.5 %



    13.9 %



    15.1 %

















    Operating income (loss)

    $  (1,229)



    $   1,115



    $  (227)



    $  3,683



    $    (2,344)



    (210.2) %



    $ (3,910)



    (106.2) %

    Operating income (loss) as a % of total revenues

    (3.7) %



    4.2 %



    (0.2) %



    4.7 %

















    Adjusted operating income (loss) (1)

    $  (924)



    $   1,536



    $      746



    $  4,901



    $    (2,460)



    (160.2) %



    $ (4,155)



    (84.8) %

    Adjusted operating income (loss) as a % of total revenues

    (2.8) %



    5.8 %



    0.8 %



    6.2 %

















    Premium revenues (by business):































    Government

    $ 22,331



    $ 17,208



    $  66,269



    $  52,680



    $    5,123



    29.8 %



    $  13,589



    25.8 %

    Commercial

    8,583



    7,437



    25,678



    21,399



    1,146



    15.4 %



    4,279



    20.0 %

     

    The following table summarizes the Health Care Benefits segment's medical membership for the respective periods:





    September 30, 2024



    June 30, 2024



    December 31, 2023



    September 30, 2023

    In thousands

    Insured



    ASC



    Total



    Insured



    ASC



    Total



    Insured



    ASC



    Total



    Insured



    ASC



    Total

    Medical membership: (4)















































    Commercial

    4,751



    14,155



    18,906



    4,702



    14,099



    18,801



    4,252



    14,087



    18,339



    4,198



    14,075



    18,273

    Medicare Advantage

    4,438



    —



    4,438



    4,342



    —



    4,342



    3,460



    —



    3,460



    3,438



    —



    3,438

    Medicare Supplement

    1,291



    —



    1,291



    1,294



    —



    1,294



    1,343



    —



    1,343



    1,352



    —



    1,352

    Medicaid

    2,077



    436



    2,513



    2,090



    443



    2,533



    2,073



    444



    2,517



    2,173



    452



    2,625

    Total medical membership

    12,557



    14,591



    27,148



    12,428



    14,542



    26,970



    11,128



    14,531



    25,659



    11,161



    14,527



    25,688

















































    Supplemental membership information:









































    Medicare Prescription Drug Plan (stand-alone)

    4,898











    4,903











    6,081











    6,092

     

    The following table summarizes the Health Care Benefits segment's days claims payable for the respective periods:





    September 30, 2024



    June 30, 2024



    March 31, 2024



    December 31, 2023



    September 30, 2023

    Days Claims Payable (7)

    44.6



    43.1



    44.5



    45.9



    50.3

     

    Supplemental Information

    (Unaudited)



    Health Services segment



    The following table summarizes the Health Services segment's performance for the respective periods:

















    Change



    Three Months Ended

    September 30,



    Nine Months Ended

    September 30,



    Three Months Ended

    September 30,

    2024 vs 2023



    Nine Months Ended

    September 30,

    2024 vs 2023

    In millions, except percentages

    2024



    2023



    2024



    2023



    $



    %



    $



    %

    Revenues:































    Products

    $ 41,208



    $ 45,019



    $  118,417



    $  133,371



    $  (3,811)



    (8.5) %



    $   (14,954)



    (11.2) %

    Services

    2,922



    1,872



    8,171



    4,326



    1,050



    56.1 %



    3,845



    88.9 %

    Net investment income (loss)

    (1)



    —



    (3)



    —



    (1)



    (100.0) %



    (3)



    (100.0) %

    Total revenues

    44,129



    46,891



    126,585



    137,697



    (2,762)



    (5.9) %



    (11,112)



    (8.1) %

    Cost of products sold

    40,381



    43,738



    116,678



    129,425



    (3,357)



    (7.7) %



    (12,747)



    (9.8) %

    Health care costs

    936



    612



    2,428



    995



    324



    52.9 %



    1,433



    144.0 %

    Gross profit (8)

    2,812



    2,541



    7,479



    7,277



    271



    10.7 %



    202



    2.8 %

    Gross margin (Gross profit as a % of total revenues) (8)

    6.4 %



    5.4 %



    5.9 %



    5.3 %

















    Operating expenses

    $       757



    $       814



    $   2,445



    $   2,145



    $        (57)



    (7.0) %



    $        300



    14.0 %

    Operating expenses as a % of total revenues

    1.7 %



    1.7 %



    1.9 %



    1.6 %

















    Operating income

    $   2,055



    $   1,727



    $   5,034



    $   5,132



    $        328



    19.0 %



    $        (98)



    (1.9) %

    Operating income as a % of total revenues

    4.7 %



    3.7 %



    4.0 %



    3.7 %

















    Adjusted operating income (1)

    $   2,204



    $   1,878



    $   5,482



    $   5,452



    $        326



    17.4 %



    $          30



    0.6 %

    Adjusted operating income as a % of total revenues

    5.0 %



    4.0 %



    4.3 %



    4.0 %

















    Revenues (by distribution channel):































    Pharmacy network (9)

    $ 24,136



    $ 27,981



    $ 66,448



    $ 83,050



    $  (3,845)



    (13.7) %



    $ (16,602)



    (20.0) %

    Mail & specialty (10)

    17,214



    17,004



    52,127



    50,378



    210



    1.2 %



    1,749



    3.5 %

    Other

    2,780



    1,906



    8,013



    4,269



    874



    45.9 %



    3,744



    87.7 %

    Net investment income (loss)

    (1)



    —



    (3)



    —



    (1)



    (100.0) %



    (3)



    (100.0) %

    Pharmacy claims processed (5) (6)

    484.1



    579.6



    1,418.2



    1,743.5



    (95.5)



    (16.5) %



    (325.3)



    (18.7) %

    Generic dispensing rate (6) (11)

    86.8 %



    87.5 %



    87.8 %



    88.1 %

















     

    Supplemental Information

    (Unaudited)



    Pharmacy & Consumer Wellness segment



    The following table summarizes the Pharmacy & Consumer Wellness segment's performance for the respective periods:

















    Change



    Three Months Ended

    September 30,



    Nine Months Ended

    September 30,



    Three Months Ended

    September 30,

    2024 vs 2023



    Nine Months Ended

    September 30,

    2024 vs 2023

    In millions, except percentages

    2024



    2023



    2024



    2023



    $



    %



    $



    %

    Revenues:































    Products

    $  31,823



    $ 28,043



    $ 89,195



    $ 83,442



    $    3,780



    13.5 %



    $    5,753



    6.9 %

    Services

    600



    831



    1,791



    2,140



    (231)



    (27.8) %



    (349)



    (16.3) %

    Net investment income (loss)

    —



    (2)



    —



    (4)



    2



    100.0 %



    4



    100.0 %

    Total revenues

    32,423



    28,872



    90,986



    85,578



    3,551



    12.3 %



    5,408



    6.3 %

    Cost of products sold

    26,032



    22,797



    72,627



    67,301



    3,235



    14.2 %



    5,326



    7.9 %

    Gross profit (8)

    6,391



    6,075



    18,359



    18,277



    316



    5.2 %



    82



    0.4 %

    Gross margin (Gross profit as a % of total revenues) (8)

    19.7 %



    21.0 %



    20.2 %



    21.4 %

















    Operating expenses

    $  4,860



    $    4,753



    $ 14,536



    $ 14,540



    $        107



    2.3 %



    $          (4)



    — %

    Operating expenses as a % of total revenues

    15.0 %



    16.5 %



    16.0 %



    17.0 %

















    Restructuring charge

    $      747



    $       —



    $      747



    $      —



    $        747



    100.0 %



    $        747



    100.0 %

    Loss on assets held for sale

    —



    —



    —



    349



    —



    — %



    (349)



    (100.0) %

    Operating income

    784



    1,322



    3,076



    3,388



    (538)



    (40.7) %



    (312)



    (9.2) %

    Operating income as a % of total revenues

    2.4 %



    4.6 %



    3.4 %



    4.0 %

















    Adjusted operating income (1)

    $  1,596



    $    1,389



    $   4,016



    $   3,936



    $        207



    14.9 %



    $          80



    2.0 %

    Adjusted operating income as a % of total revenues

    4.9 %



    4.8 %



    4.4 %



    4.6 %

















    Revenues (by major goods/service lines):































    Pharmacy

    $  26,666



    $ 22,977



    $ 73,463



    $ 67,371



    $    3,689



    16.1 %



    $    6,092



    9.0 %

    Front Store

    5,196



    5,371



    15,847



    16,597



    (175)



    (3.3) %



    (750)



    (4.5) %

    Other

    561



    526



    1,676



    1,614



    35



    6.7 %



    62



    3.8 %

    Net investment income (loss)

    —



    (2)



    —



    (4)



    2



    100.0 %



    4



    100.0 %

    Prescriptions filled (5) (6)

    431.6



    407.1



    1,269.6



    1,217.6



    24.5



    6.0 %



    52.0



    4.3 %

    Same store sales increase (decrease): (12)































    Total

    15.5 %



    8.8 %



    9.1 %



    10.4 %

















    Pharmacy

    19.5 %



    11.9 %



    12.1 %



    13.0 %

















    Front Store

    (1.1) %



    (2.2) %



    (2.5) %



    1.6 %

















    Prescription volume (6)

    9.1 %



    2.7 %



    7.1 %



    3.7 %

















    Generic dispensing rate (6) (11)

    88.2 %



    88.3 %



    89.5 %



    89.1 %

















     

    Supplemental Information

    (Unaudited)



    Corporate/Other segment



    The following table summarizes the Corporate/Other segment's performance for the respective periods:

















    Change



    Three Months Ended

    September 30,



    Nine Months Ended

    September 30,



    Three Months Ended

    September 30,

    2024 vs 2023



    Nine Months Ended

    September 30,

    2024 vs 2023

    In millions, except percentages

    2024



    2023



    2024



    2023



    $



    %



    $



    %

    Revenues:































    Premiums

    $          11



    $          12



    $          36



    $          38



    $          (1)



    (8.3) %



    $          (2)



    (5.3) %

    Services

    3



    1



    7



    5



    2



    200.0 %



    2



    40.0 %

    Net investment income

    128



    92



    325



    333



    36



    39.1 %



    (8)



    (2.4) %

    Total revenues

    142



    105



    368



    376



    37



    35.2 %



    (8)



    (2.1) %

    Cost of products sold

    —



    —



    —



    1



    —



    — %



    (1)



    (100.0) %

    Health care costs

    49



    61



    142



    163



    (12)



    (19.7) %



    (21)



    (12.9) %

    Operating expenses

    449



    507



    1,539



    1,538



    (58)



    (11.4) %



    1



    0.1 %

    Restructuring charges

    422



    11



    422



    507



    411



    3,736.4 %



    (85)



    (16.8) %

    Operating loss

    (778)



    (474)



    (1,735)



    (1,833)



    (304)



    (64.1) %



    98



    5.3 %

    Adjusted operating loss (1)

    (329)



    (347)



    (996)



    (982)



    18



    5.2 %



    (14)



    (1.4) %

     

    Supplemental Information

    (Unaudited)



    The following table shows the components of the change in the consolidated health care costs payable during the nine months ended September 30, 2024 and 2023:





    Nine Months Ended

    September 30,

    In millions

    2024



    2023

    Health care costs payable, beginning of the period

    $       12,049



    $       10,142

    Less: Reinsurance recoverables

    5



    5

    Less: Impact of discount rate on long-duration insurance reserves (a)

    (23)



    8

    Health care costs payable, beginning of the period, net

    12,067



    10,129

    Acquisitions, net

    —



    1,098

    Add: Components of incurred health care costs







    Current year

    85,541



    64,183

    Prior years (b)

    (845)



    (679)

    Total incurred health care costs (c)

    84,696



    63,504

    Less: Claims paid







    Current year

    71,356



    52,952

    Prior years

    10,886



    9,207

    Total claims paid

    82,242



    62,159

    Health care costs payable, end of the period, net

    14,521



    12,572

    Add: Premium deficiency reserve

    670



    —

    Add: Reinsurance recoverables

    65



    4

    Add: Impact of discount rate on long-duration insurance reserves (a)

    (19)



    (26)

    Health care costs payable, end of the period

    $       15,237



    $       12,550

     

    _____________________________________________

    (a)

    Reflects the difference between the current discount rate and the locked-in discount rate on long-duration insurance reserves which is recorded within accumulated other comprehensive income (loss) on the unaudited condensed consolidated balance sheets.

    (b)

    Negative amounts reported for incurred health care costs related to prior years result from claims being settled for amounts less than originally estimated.

    (c)

    Total incurred health care costs for the nine months ended September 30, 2024 and 2023 in the table above exclude $70 million and $62 million, respectively, of health care costs recorded in the Health Care Benefits segment that are included in other insurance liabilities on the unaudited condensed consolidated balance sheets and $142 million and $163 million, respectively, of health care costs recorded in the Corporate/Other segment that are included in other insurance liabilities on the unaudited condensed consolidated balance sheets. Total incurred health care costs for the nine months ended September 30, 2024 also exclude $670 million for premium deficiency reserves related to the Company's Medicare, individual exchange and Medicaid product lines.

     

    Endnotes

    (1) The Company defines adjusted operating income as operating income (GAAP measure) excluding the impact of amortization of intangible assets, net realized capital gains or losses and other items, if any, that neither relate to the ordinary course of the Company's business nor reflect the Company's underlying business performance, such as acquisition-related transaction and integration costs, restructuring charges, office real estate optimization charges, opioid litigation charges and losses on assets held for sale. The CODM uses adjusted operating income as its principal measure of segment performance as it enhances the CODM's ability to compare past financial performance with current performance and analyze underlying business performance and trends. The consolidated measure is not determined in accordance with GAAP and should not be considered a substitute for, or superior to, the most directly comparable GAAP measure, consolidated operating income. See "Non-GAAP Financial Information" earlier in this press release for additional information regarding the items excluded from consolidated operating income in determining consolidated adjusted operating income.

    (2) GAAP diluted earnings per share and Adjusted EPS, respectively, are calculated by dividing net income attributable to CVS Health and adjusted income attributable to CVS Health by the Company's weighted average diluted shares outstanding. The Company defines adjusted income attributable to CVS Health as net income attributable to CVS Health (GAAP measure) excluding the impact of amortization of intangible assets, net realized capital gains or losses and other items, if any, that neither relate to the ordinary course of the Company's business nor reflect the Company's underlying business performance, such as acquisition-related transaction and integration costs, restructuring charges, office real estate optimization charges, opioid litigation charges, losses on assets held for sale, as well as the corresponding income tax benefit or expense related to the items excluded from adjusted income attributable to CVS Health. See "Non-GAAP Financial Information" earlier in this press release for additional information regarding the items excluded from net income attributable to CVS Health in determining adjusted income attributable to CVS Health.

    (3) Medical benefit ratio is calculated by dividing the Health Care Benefits segment's health care costs by premium revenues and represents the percentage of premium revenues spent on medical benefits for the segment's insured members. Management uses MBR to assess the underlying business performance and underwriting of its insurance products, understand variances between actual results and expected results and identify trends in period-over-period results. MBR provides management and investors with information useful in assessing the operating results of the Health Care Benefits segment's insured products.

    (4) Medical membership represents the number of members covered by the Health Care Benefits segment's insured and ASC medical products and related services at a specified point in time. Management uses this metric to understand variances between actual medical membership and expected amounts as well as trends in period-over-period results. This metric provides management and investors with information useful in understanding the impact of medical membership on the Health Care Benefits segment's total revenues and operating results.

    (5) Pharmacy claims processed represents the number of prescription claims processed through the Company's pharmacy benefits manager and dispensed by either its retail network pharmacies or the Company's mail and specialty pharmacies. Prescriptions filled represents the number of prescriptions dispensed through the Pharmacy & Consumer Wellness segment's retail and long-term care pharmacies and infusion services operations. Management uses these metrics to understand variances between actual claims processed and prescriptions dispensed, respectively, and expected amounts as well as trends in period-over-period results. These metrics provide management and investors with information useful in understanding the impact of pharmacy claim volume and prescription volume, respectively, on segment total revenues and operating results.

    (6) Includes an adjustment to convert 90-day prescriptions to the equivalent of three 30-day prescriptions. This adjustment reflects the fact that these prescriptions include approximately three times the amount of product days supplied compared to a normal prescription. 

    (7) Days claims payable is calculated by dividing the Health Care Benefits segment's health care costs payable at the end of each quarter by its average health care costs per day during such quarter. Management and investors use this metric as an indicator of the adequacy of the Health Care Benefits segment's health care costs payable liability at the end of each quarter and as an indicator of changes in such adequacy over time.

    (8) Gross profit is calculated as the segment's total revenues less its cost of products sold, and, for the Health Services segment, health care costs. Gross margin is calculated by dividing the segment's gross profit by its total revenues and represents the percentage of total revenues that remains after incurring direct costs associated with the segment's products sold and services provided. Gross margin provides investors with information that may be useful in assessing the operating results of the Company's Health Services and Pharmacy & Consumer Wellness segments.

    (9) Health Services pharmacy network revenues relate to claims filled at retail and specialty retail pharmacies, including the Company's retail pharmacies and LTC pharmacies, as well as activity associated with Maintenance Choice®, which permits eligible client plan members to fill their maintenance prescriptions through mail order delivery or at a CVS pharmacy retail store for the same price as mail order.

    (10) Health Services mail and specialty revenues relate to specialty mail claims inclusive of Specialty Connect® claims picked up at a retail pharmacy, as well as mail order and specialty claims fulfilled by the Pharmacy & Consumer Wellness segment.

    (11) Generic dispensing rate is calculated by dividing the segment's generic drug claims processed or prescriptions filled by its total claims processed or prescriptions filled. Management uses this metric to evaluate the effectiveness of the business at encouraging the use of generic drugs when they are available and clinically appropriate, which aids in decreasing costs for client members and retail customers. This metric provides management and investors with information useful in understanding trends in segment total revenues and operating results.  

    (12) Same store sales and prescription volume represent the change in revenues and prescriptions filled in the Company's retail pharmacy stores that have been operating for greater than one year and digital sales initiated online or through mobile applications and fulfilled through the Company's distribution centers, expressed as a percentage that indicates the increase or decrease relative to the comparable prior period. Same store metrics exclude revenues and prescriptions from LTC and infusion services operations. Management uses these metrics to evaluate the performance of existing stores on a comparable basis and to inform future decisions regarding existing stores and new locations. Same-store metrics provide management and investors with information useful in understanding the portion of current revenues and prescriptions resulting from organic growth in existing locations versus the portion resulting from opening new stores.

    CVS Health logo (PRNewsFoto/CVS Health)

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cvs-health-corporation-reports-third-quarter-2024-results-302297277.html

    SOURCE CVS Health Corporation

    Get the next $CVS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CVS

    DatePrice TargetRatingAnalyst
    2/13/2025$55.00 → $75.00Market Perform → Outperform
    Leerink Partners
    2/12/2025Neutral → Overweight
    Cantor Fitzgerald
    1/30/2025Hold → Buy
    Edward Jones
    12/3/2024$66.00Hold → Buy
    Deutsche Bank
    11/18/2024$60.00 → $66.00Equal Weight → Overweight
    Wells Fargo
    10/10/2024$63.00 → $82.00Equal Weight → Overweight
    Barclays
    10/4/2024$59.00 → $85.00Hold → Buy
    TD Cowen
    5/30/2024$61.00Neutral
    Robert W. Baird
    More analyst ratings

    $CVS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AM Best Affirms Credit Ratings of CVS Health Corporation's Aetna Inc. Subsidiaries

      AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICRs) of "a" (Excellent) of Aetna Life Insurance Company (ALIC) (Hartford, CT) and the other members of Aetna Health & Life Group, which are operating entities of Aetna Inc. (Aetna) and wholly owned subsidiaries of CVS Health Corporation (CVS Health) (NYSE:CVS). (Please see below for a detailed listing of the companies.) Concurrently, AM Best has affirmed the FSR of A (Excellent) and the Long-Term ICR of "a" (Excellent) of Allina Health and Aetna Insurance Company (Allina Health) (St. Louis Park, MN). Allina Health is a joint venture subsidiary with subsidiaries of A

      5/8/25 4:47:00 PM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Glenview Capital Issues Statement on CVS Health

      NEW YORK, May 6, 2025 /PRNewswire/ -- One year ago, we established a concentrated position in shares of CVS Health (NYSE:CVS). Since our purchases in May 2024, CVS shares have generated a total return of 25% reflecting initial progress in the long-term cultural and operational turnaround underway at the Company.  Our position size afforded us the scale necessary to constructively engage with the Board, Management, and fellow Shareholders in Q3 2024 on a multi-faceted performance improvement plan: Board Refreshment – The Board welcomed four new Directors including Larry Robbins, Glenview's CEO, and recently appointed a strong Lead Independent Director.  The entire Board is operating cooperat

      5/6/25 4:15:00 PM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • CVS HEALTH CORPORATION REPORTS FIRST QUARTER 2025 RESULTS AND UPDATES FULL-YEAR 2025 GUIDANCE

      First Quarter Financial Highlights Total revenues increased to $94.6 billion, up 7.0% compared to prior yearGAAP diluted EPS of $1.41 and Adjusted EPS of $2.25Generated cash flow from operations of $4.6 billionOperational Highlights CVS Health to exit the individual exchange businessAetna® introduces new solutions to ease the patient and provider experienceCVS Caremark® makes formulary update to improve access to GLP-1 drugs2025 Full-Year Guidance Revised GAAP diluted EPS guidance range to $4.23 to $4.43 from $4.58 to $4.83Raised Adjusted EPS guidance range to $6.00 to $6.20 from $5.75 to $6.00Raised cash flow from operations guidance to approximately $7.0 billion from approximately $6.5 bil

      5/1/25 6:30:00 AM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $CVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Robbins Larry sold $253,695,413 worth of shares (3,750,000 units at $67.65) (SEC Form 4)

      4 - CVS HEALTH Corp (0000064803) (Issuer)

      5/6/25 4:15:27 PM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • EVP and Group President Shah Prem S covered exercise/tax liability with 1,308 shares and was granted 26,478 shares, increasing direct ownership by 20% to 58,166 units (SEC Form 4)

      4 - CVS HEALTH Corp (0000064803) (Issuer)

      4/3/25 4:43:05 PM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • EVP and President, Aetna Nelson Steven H was granted 21,329 shares (SEC Form 4)

      4 - CVS HEALTH Corp (0000064803) (Issuer)

      4/3/25 4:29:13 PM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $CVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by CVS Health Corporation

      SC 13G - CVS HEALTH Corp (0000064803) (Subject)

      11/13/24 1:00:57 PM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form SC 13G/A filed by CVS Health Corporation (Amendment)

      SC 13G/A - CVS HEALTH Corp (0000064803) (Subject)

      2/13/24 5:02:40 PM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form SC 13G/A filed by CVS Health Corporation (Amendment)

      SC 13G/A - CVS HEALTH Corp (0000064803) (Subject)

      2/9/23 11:16:32 AM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $CVS
    Leadership Updates

    Live Leadership Updates

    See more
    • CVS Health Announces Chief Financial Officer Transition Plan; Appoints Chief Medical Officer

      WOONSOCKET, R.I., April 8, 2025 /PRNewswire/ -- CVS Health® (NYSE:CVS) today announced two leadership updates. Brian Newman has been named executive vice president and chief financial officer designate, effective April 21. He will succeed current chief financial officer, Tom Cowhey, who will transition to serve as a strategic advisor to president and chief executive officer David Joyner, effective May 12.Amy Compton-Phillips, M.D., is the company's new executive vice president and chief medical officer, effective May 19, also reporting to David Joyner.Based on year-to-date res

      4/8/25 6:30:00 AM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • CVS Health Foundation helps address barriers to care and provides resources for individuals with chronic health conditions in Hartford

      Foundation announces $2 million in new Health Zones funding to support at-risk populations WOONSOCKET, R.I., March 6, 2025 /PRNewswire/ -- The CVS Health® Foundation today announced $2 million in new Health Zones funding to support the Hispanic Health Council's Family Wellness Center and its agency partners, all located in Hartford, Connecticut. This funding will help address critical gaps in the health care and social system for individuals with chronic health conditions by increasing access to comprehensive health care services and resources. "A variety of interconnected fac

      3/6/25 8:30:00 AM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • CVS Health announces Pharmacy and Consumer Wellness leadership appointments

      WOONSOCKET, R.I., Dec. 3, 2024 /PRNewswire/ -- CVS Health® (NYSE: CVS) today announced that Len Shankman will be president, Pharmacy and Consumer Wellness (PCW), reporting to Prem Shah, group president, CVS Health. In addition, the company announced the appointment of Lucille Accetta, RPh, MPH, MBA as chief pharmacy officer, also reporting to Shah. Both appointments are effective immediately. As president, Pharmacy and Consumer Wellness, Shankman will oversee the front store and retail pharmacy businesses across the company's more than 9,000 CVS Pharmacy locations. In his new

      12/3/24 7:00:00 AM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $CVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • CVS Health upgraded by Leerink Partners with a new price target

      Leerink Partners upgraded CVS Health from Market Perform to Outperform and set a new price target of $75.00 from $55.00 previously

      2/13/25 7:04:02 AM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • CVS Health upgraded by Cantor Fitzgerald

      Cantor Fitzgerald upgraded CVS Health from Neutral to Overweight

      2/12/25 2:18:18 PM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • CVS Health upgraded by Edward Jones

      Edward Jones upgraded CVS Health from Hold to Buy

      1/30/25 7:09:02 AM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $CVS
    SEC Filings

    See more
    • SEC Form 13F-HR filed by CVS Health Corporation

      13F-HR - CVS HEALTH Corp (0000064803) (Filer)

      5/2/25 4:08:15 PM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form 10-Q filed by CVS Health Corporation

      10-Q - CVS HEALTH Corp (0000064803) (Filer)

      5/1/25 6:35:46 AM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • CVS Health Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - CVS HEALTH Corp (0000064803) (Filer)

      5/1/25 6:32:09 AM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $CVS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mahoney Michael F bought $2,001,000 worth of shares (30,000 units at $66.70), increasing direct ownership by 321% to 39,356 units (SEC Form 4)

      4 - CVS HEALTH Corp (0000064803) (Issuer)

      2/19/25 12:35:35 PM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Ludwig Edward J bought $53,879 worth of shares (1,000 units at $53.88), increasing direct ownership by 5% to 21,630 units (SEC Form 4)

      4 - CVS HEALTH Corp (0000064803) (Issuer)

      5/2/24 4:31:44 PM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Mahoney Michael F bought $500,294 worth of shares (9,181 units at $54.49), increasing direct ownership by 5,246% to 9,356 units (SEC Form 4)

      4 - CVS HEALTH Corp (0000064803) (Issuer)

      5/2/24 4:30:49 PM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $CVS
    Financials

    Live finance-specific insights

    See more
    • AM Best Affirms Credit Ratings of CVS Health Corporation's Aetna Inc. Subsidiaries

      AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICRs) of "a" (Excellent) of Aetna Life Insurance Company (ALIC) (Hartford, CT) and the other members of Aetna Health & Life Group, which are operating entities of Aetna Inc. (Aetna) and wholly owned subsidiaries of CVS Health Corporation (CVS Health) (NYSE:CVS). (Please see below for a detailed listing of the companies.) Concurrently, AM Best has affirmed the FSR of A (Excellent) and the Long-Term ICR of "a" (Excellent) of Allina Health and Aetna Insurance Company (Allina Health) (St. Louis Park, MN). Allina Health is a joint venture subsidiary with subsidiaries of A

      5/8/25 4:47:00 PM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • CVS HEALTH CORPORATION REPORTS FIRST QUARTER 2025 RESULTS AND UPDATES FULL-YEAR 2025 GUIDANCE

      First Quarter Financial Highlights Total revenues increased to $94.6 billion, up 7.0% compared to prior yearGAAP diluted EPS of $1.41 and Adjusted EPS of $2.25Generated cash flow from operations of $4.6 billionOperational Highlights CVS Health to exit the individual exchange businessAetna® introduces new solutions to ease the patient and provider experienceCVS Caremark® makes formulary update to improve access to GLP-1 drugs2025 Full-Year Guidance Revised GAAP diluted EPS guidance range to $4.23 to $4.43 from $4.58 to $4.83Raised Adjusted EPS guidance range to $6.00 to $6.20 from $5.75 to $6.00Raised cash flow from operations guidance to approximately $7.0 billion from approximately $6.5 bil

      5/1/25 6:30:00 AM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • CVS Health to hold first quarter 2025 earnings conference call

      WOONSOCKET, R.I., April 3, 2025 /PRNewswire/ -- CVS Health® (NYSE:CVS) will hold a conference call with analysts and investors on Thursday, May 1st, 2025, at 8:00 a.m. ET to discuss first quarter 2025 financial results. An audio webcast of the event will be broadcast simultaneously on the Investor Relations portion of the CVS Health website at investors.cvshealth.com where it will be archived for a period of one year. About CVS HealthCVS Health is a leading health solutions company building a world of health around every consumer, wherever they are. As of December 31, 2024, th

      4/3/25 9:00:00 AM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples